ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP8-21 Change in Suspect COVID-19 Diagnosis Code
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 27, 2021
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 2221 - 2230 လၢ 3159 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP4-21 Commercial Pharmacy Benefit Exclusion for OxlumoTM
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 27, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP5-21 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Sucraid® (sacrosidase) PAQL
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 27, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP2-21 Update for New to Market Medical Drugs: Aducanumab, Casimersen, Evinacumab, Idecabtagene Vicleucel, and Pegunigalsidase Alfa
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 13, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP1-21 Pharmacy Benefit Update – Revised Drug-Related Prior Authorization (PA) Requirement Notification – Effective March 1, 2021
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 13, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP3-21 Commercial and MHCP Pharmacy Benefit Exclusion for Barhemsys® and Monoferric®
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 13, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P1-21 Retro Reviews for Post-Acute Care and Home Health Prior Authorizations
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 04, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
2021 January Bulletins
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 04, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P2-21 Hospital Transfer Notification Process for Load Leveling
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 04, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P81R1-20 Update: eviCore Healthcare Specialty Utilization Management (UM) Program - Cardiology and Radiology Clinical Guideline Updates for Fully Insured Commercial and Medicare Advantage Subscribers
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 04, 2021